Pen­ny stock biotech His­to­gen stops de­vel­op­ment pro­grams and con­sid­ers strate­gic al­ter­na­tives

The pen­ny stock biotech His­to­gen has halt­ed its de­vel­op­ment pro­grams and is ex­plor­ing strate­gic al­ter­na­tives for the fu­ture of the im­mune sys­tem-fo­cused com­pa­ny, a few months af­ter re­port­ing that it on­ly had cash run­way through Jan­u­ary 2024.

His­to­gen said in a state­ment that it’s con­sid­er­ing an ac­qui­si­tion, merg­er, re­verse merg­er, as­set sale, fi­nanc­ing al­ter­na­tives, li­cens­ing, “or oth­er strate­gic trans­ac­tions” to stay afloat.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER